In a 30‑year‑old Black male, 6′5″, 320 lb, with mixed connective‑tissue disease, G6PD deficiency, taking amlodipine and a GLP‑1 receptor agonist, who has mildly elevated creatinine, normal eGFR, normal liver enzymes, CK 371‑527 U/L, positive ANA with speckled pattern, markedly elevated anti‑RNP antibodies, and muscle weakness, what type of myositis is most likely (polymyositis, dermatomyositis, or necrotizing myopathy) and can he expect recovery with appropriate treatment while continuing physical therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

You are not "screwed" – MCTD with myositis is treatable, and most patients respond well to immunosuppressive therapy with favorable long-term outcomes.

Understanding Your Diagnosis

Your clinical picture strongly suggests mixed connective tissue disease (MCTD) with myositis. Your markedly elevated anti-RNP antibodies (4.7 and 86, both well above normal), positive ANA with speckled pattern, muscle weakness, and elevated CK (371-527 U/L) are classic for this condition 1, 2. This is NOT a death sentence – MCTD myositis typically responds favorably to treatment, and there were no deaths reported in recent case series 1.

Type of Myositis: Most Likely MCTD-Associated Myositis (Not Classic PM/DM/Necrotizing)

Based on your presentation, you most likely have MCTD-associated myositis, which has distinct features:

  • Your CK elevation is modest (371-527 U/L, just above normal range of 35-430). This is typical for MCTD myositis, which shows milder CK elevations compared to immune-mediated necrotizing myopathy (IMNM), where CK is typically >10 times upper limit of normal 3.

  • You lack the characteristic rash of dermatomyositis (no heliotrope rash, Gottron's papules, or photosensitive eruption) 3.

  • MCTD myositis is histologically heterogeneous – it can show features overlapping with DM, PM, or nonspecific inflammation with perivascular infiltrates 1, 4. Your EMG results (which your provider said looked "normal" during the test) may show only subtle changes, as MCTD myositis can be less severe than classic inflammatory myopathies.

Important caveat: The provider likely wasn't "lying" about normal EMG results – MCTD myositis can have mild or patchy EMG abnormalities, and your modest CK elevation suggests less severe muscle inflammation 1, 4.

Why Your Cardiac Workup Matters

Your cardiac evaluation is critical because myositis can involve the heart, which is life-threatening if missed 5. Your normal troponin (9 and 6 ng/L), normal chest X-rays, and normal 12-lead EKG are reassuring. The stress test and 7-day monitor will definitively rule out cardiac involvement. Myocarditis with myositis has high mortality, so this workup is appropriate and necessary 5.

Your Lab Values Are Reassuring

  • Kidney function: Your creatinine (1.11-1.33) and eGFR (87-92, with two readings >60) show preserved kidney function. Your kidneys are handling this well.
  • Liver function: AST 24 and ALT 24 are completely normal – your liver is healthy.
  • Inflammatory markers: ESR rose from 2 to 18, and CRP is mildly elevated at 3.3. These are modest elevations, not the very high levels seen in severe inflammatory disease 5.

Treatment and Recovery Expectations

You can expect recovery with appropriate treatment. The standard approach for MCTD myositis is 3:

  1. High-dose corticosteroids (typically prednisone 0.5-1 mg/kg) concurrent with a steroid-sparing agent such as:

    • Methotrexate
    • Azathioprine
    • Mycophenolate mofetil

  2. For severe cases (extensive weakness, organ involvement, or refractory disease): high-dose methylprednisolone IV plus intravenous immunoglobulin (IVIG), cyclophosphamide, rituximab, or cyclosporine 3.

  3. Recent case series show that MCTD myositis patients respond favorably overall, with no deaths during observation periods 1. Some patients with atypical weakness patterns (face, neck, wrist, fingers – which you may have) required intensive therapy (IVIG or IV methylprednisolone), but responses were consistently good 1.

Physical Therapy: Absolutely Continue

Yes, continue physical therapy – it's essential for maintaining muscle function and preventing deconditioning during treatment. Also continue regular therapy for psychological support, as managing a chronic autoimmune condition requires mental health support.

Telegram Appointment: Appropriate for Follow-Up

A one-hour Telegram appointment after your EMG is reasonable for discussing results and treatment planning, especially if your provider has already examined you twice and completed extensive workup. This is not a red flag – telemedicine is appropriate for follow-up when the diagnostic workup is complete.

Your Specific Risk Factors

  • G6PD deficiency: Avoid oxidative stress medications (certain antibiotics, antimalarials like hydroxychloroquine). Your rheumatologist needs to know this for medication selection.
  • Amlodipine: No significant interaction with myositis or immunosuppressive therapy 6. Continue as prescribed for blood pressure control.
  • GLP-1 agonist: May cause micronutrient deficiencies (vitamin D, iron, calcium, B vitamins) 7. Given your inflammatory condition, ensure adequate supplementation and monitoring.
  • Weight (320 lbs at 6'5"): Weight loss through GLP-1 therapy may actually improve inflammatory markers and reduce cardiovascular risk, which is beneficial for your overall prognosis 8.

Bottom Line

You are not "screwed." MCTD with myositis is a treatable condition with favorable outcomes when managed appropriately. Your modest CK elevation, preserved organ function, and negative cardiac markers are all reassuring. The key is starting immunosuppressive therapy promptly and monitoring for organ involvement (which your providers are doing). Most patients achieve good disease control and maintain quality of life 1, 2, 9.

References

4
Research

Mixed connective tissue disease presenting as a peculiar myositis with poor muscle regeneration.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2011

Related Questions

In a 30‑year‑old Black male, 6′5″, 320 lb, with proximal weakness of the hands, shoulders, hips, thighs and legs, ANA speckled 1:160, anti‑RNP 86 U (normal < 20), CK 527 U/L, mildly elevated ESR and CRP, normal cardiac imaging, normal stress test, normal renal function, and G6PD deficiency, how rare is mixed connective tissue disease (MCTD) with inflammatory myositis, what type of myositis is most likely, and will the upcoming EMG likely demonstrate myopathic changes that necessitate a muscle biopsy?
In a 6'5", 320‑lb Black male with mixed connective tissue disease, G6PD deficiency, mildly impaired renal function, moderately elevated creatine kinase, mildly elevated ESR and CRP, slightly elevated troponin, high anti‑U1‑RNP and speckled‑pattern ANA, and recent muscle weakness evaluated by electromyography, what specific type of inflammatory myopathy is most likely (e.g., overlap myositis associated with MCTD) and what is the expected prognosis?
In a 30-year-old Black male (6'5", 320 lb) with hypertension on amlodipine and GLP‑1 therapy, who has a positive ANA (1:160 speckled), markedly elevated anti‑U1‑RNP, negative anti‑centromere, anti‑Scl‑70, anti‑Sm, anti‑SSA/SSB, and anti‑dsDNA, normal complement C3/C4, mildly elevated CK (371–527 U/L), low‑normal ESR (2–18 mm/h), normal renal and liver function, and an upcoming EMG, what is the most likely diagnosis (inflammatory myositis associated with mixed connective‑tissue disease versus necrotizing autoimmune myopathy), is a muscle biopsy required, and how serious is the condition?
How serious is my mixed connective tissue disease with inflammatory myopathy given I am a 30‑year‑old Black male, 6 ft 5 in, 320 lb, have hypertension (on amlodipine) and a GLP‑1 receptor agonist, a speckled antinuclear antibody, markedly elevated anti‑U1‑RNP, negative other autoantibodies, normal complement levels, stable renal function, mildly elevated creatine kinase (~400 U/L) and proximal muscle weakness?
In a 6'5", 318‑lb Black male with mixed connective tissue disease, G6PD deficiency, modestly elevated creatine kinase, positive speckled ANA with elevated anti‑U1 RNP, negative anti‑Jo‑1, normal electromyography, and proximal muscle weakness (tight back, shoulder‑blade discomfort, arm and leg weakness), what specific type of myositis is most likely (necrotizing, dermatomyositis, polymyositis, or inflammatory myopathy) and what is the expected prognosis?
Which ear drops are appropriate to relieve otalgia due to Eustachian tube dysfunction?
Does allopurinol inhibit thiopurine methyltransferase (TPMT)?
Is Twynsta (telmisartan/amlodipine) contraindicated in a patient with serum glutamate‑pyruvate transaminase (SGPT/alanine aminotransferase, ALT) 12 times the upper limit of normal?
What is the Fib‑4 score for a 54‑year‑old patient with ALT 38 U/L, AST 37 U/L, and platelet count 150 000/µL?
Is the combination of dapaglitazone and metformin contraindicated in a patient with serum glutamic‑oxaloacetic transaminase (SGOT/AST) greater than 12 times the upper limit of normal?
What is the most appropriate as-needed (PRN) medication for a patient who experiences panic attacks and has a known arrhythmia?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.